Skye Bioscience Announces Participation in February Conferences

SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following investor conferences: BIO CEO & Investor ConferenceNew YorkPanel: Obesity: Next Medicines with ImpactMonday, February 10, 2025, 11:00 AM – 11:50 AM ET Oppenheimer 35th Healthcare Life Sciences Conference VirtualCorporate overview Wedne

This article was originally published here.